Five core IP legal principles in life sciences

Comprehensive and effective IP due diligence in life science transactions is essential. This is especially true of emerging and growth life science companies, where a single asset protected by strong IP can command hundreds of millions of dollars.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

BioNTech fires shots at Moderna's next-generation vaccine

20 February 2026 The German biotech claims the newly approved vaccine infringes its mRNA patent, deepening an already complex feud with billions of dollars at stake.

Americas

Abbott unit defends European protection for heart valve ‘cuff’ design

19 February 2026 An EPO appeals board has denied Boston Scientific’s bid to revoke St Jude Medical’s transcatheter aortic valve replacement (TAVR) patent, but declined to hand a complete victory to the patent owner.

Americas

Natera targets ex-employee over mass file download before rival move

19 February 2026 The genetic testing firm claims that a former oncology specialist stole hundreds of confidential files in the dead of night, days before moving to a competitor.

More features

BioNTech fires shots at Moderna's next-generation vaccine

Mintz gains ex-Winston & Strawn partner and ITC expert

Abbott unit defends European protection for heart valve ‘cuff’ design

Natera targets ex-employee over mass file download before rival move

Danaher moves to acquire Masimo in $9.9bn deal

Emotional Perception exclusive: ‘We are now very much open for business’

New rankings recognise top US patent firms and lawyers

Norton Rose Fulbright expands pharma and biotech disputes team

Five core IP legal principles in life sciences

More on this story

Editor's picks

Editor's picks

More features